Regulation of psmb5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (stat3): Potential role in bortezomib-mediated anticancer therapy

Journal of Biological Chemistry

Volumn 289, Issue 18, 2014, Pages 12612-12622

  Vangala, Janakiram Reddy ^a   Dudem, Srikanth ^a   Jain, Nishant ^a   Kalivendi, Shasi V ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CATALYST ACTIVITY; MAMMALS;

ACTIVATED SIGNAL; ANTI-CANCER THERAPIES; CATALYTIC SUBUNITS; PROTEASOMES;

CHEMICAL ACTIVATION;

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; BORTEZOMIB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN PSMB5; RESVERATROL; STAT3 PROTEIN; STATTIC; UNCLASSIFIED DRUG; WP 1066;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG PROTEIN BINDING; DRUG TARGETING; GENE; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE SILENCING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PSMB5 GENE; SIGNAL TRANSDUCTION; STAT3 GENE; TRANSCRIPTION REGULATION; UPREGULATION;

CANCER; CHEMORESISTANCE; EPIDERMAL GROWTH FACTOR (EGF); PROTEASOME; STAT3;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; HEK293 CELLS; HELA CELLS; HUMANS; NEOPLASMS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEIN SUBUNITS; PYRAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STAT3 TRANSCRIPTION FACTOR; TYROSINE; UP-REGULATION;

EID: 84899749396     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.542829     Document Type: Article

References (51)

1. Coux, O., Tanaka, K., and Goldberg, A. L. (1996) Structure and functions of the 20 S and 26 S proteasomes. Annu. Rev. Biochem. 65, 801-847
2. Goldberg, A. L. (2003) Protein degradation and protection against misfolded or damaged proteins. Nature 426, 895-899
3. Demartino, G. N., and Gillette, T. G. (2007) Proteasomes: machines for all reasons. Cell 129, 659-662
4. Tanaka, K. (2009) The proteasome: overview of structure and functions. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 85, 12-36
5. Adams, J. (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5, 417-421
6. Kisselev, A. F., van der Linden, W. A., and Overkleeft, H. S. (2012) Proteasome inhibitors: an expanding army attacking a unique target. Chem. Biol. 19, 99-115
7. Chen, D., Frezza, M., Schmitt, S., Kanwar, J., and Dou, Q. P. (2011) Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr. Cancer Drug Targets 11, 239-253
8. Meiners, S., Heyken, D., Weller, A., Ludwig, A., Stangl, K., Kloetzel, P. M., and Krüger, E. (2003) Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of mammalian proteasomes. J. Biol. Chem. 278, 21517-21525
9. Wang, X. J., Yu, J., Wong, S. H., Cheng, A. S., Chan, F. K., Ng, S. S., Cho, C. H., Sung, J. J., and Wu, W. K. (2013) A novel crosstalk between two major protein degradation systems: regulation of proteasomal activity by autophagy. Autophagy 9, 1500-1508
10. Steffen, J., Seeger, M., Koch, A., and Krüger, E. (2010) Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. Mol. Cell 40, 147-158
11. Radhakrishnan, S. K., Lee, C. S., Young, P., Beskow, A., Chan, J. Y., and Deshaies, R. J. (2010) Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol. Cell 38, 17-28
12. Kwak, M. K., Wakabayashi, N., Greenlaw, J. L., Yamamoto, M., and Kensler, T. W. (2003) Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol. Cell. Biol. 23, 8786-8794
13. Lee, C. S., Lee, C., Hu, T., Nguyen, J. M., Zhang, J., Martin, M. V., Vawter, M. P., Huang, E. J., and Chan, J. Y. (2011) Loss of nuclear factor E2-related factor 1 in the brain leads to dysregulation of proteasome gene expression and neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 108, 8408-8413
14. Xie, Y. (2010) Feedback regulation of proteasome gene expression and its implications in cancer therapy. Cancer Metastasis Rev. 29, 687-693
15. Ren, S., Smith, M. J., Louro, I. D., McKie-Bell, P., Bani, M. R., Wagner, M., Zochodne, B., Redden, D. T., Grizzle, W. E., Wang, N., Smith, D. I., Herbst, R. A., Bardenheuer, W., Opalka, B., Schütte, J., Trent, J. M., Ben-David, Y., and Ruppert, J. M. (2000) The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma. Oncogene 19, 1419-1427
16. Chen, L., and Madura, K. (2005) Increased proteasome activity, ubiquitinconjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res. 65, 5599-5606
17. Bazzaro, M., Lee, M. K., Zoso, A., Stirling, W. L., Santillan, A., Shih, I. M., and Roden, R. B. (2006) Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res. 66, 3754-3763
18. Wyke, S. M., Russell, S. T., and Tisdale, M. J. (2004) Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-B activation. Br. J. Cancer 91, 1742-1750
19. Kraus, M., Rückrich, T., Reich, M., Gogel, J., Beck, A., Kammer, W., Berkers, C. R., Burg, D., Overkleeft, H., Ovaa, H., and Driessen, C. (2007) Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia 21, 84-92
20. Arlt, A., Bauer, I., Schafmayer, C., Tepel, J., Müerköster, S. S., Brosch, M., Röder, C., Kalthoff, H., Hampe, J., Moyer, M. P., Fölsch, U. R., and Schäfer, H. (2009) Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene 28, 3983-3996
21. Jain, N., Gupta, S., Sudhakar, C., Radha, V., and Swarup, G. (2005) Role of p73 in regulating human caspase-1 gene transcription induced by interferon- and cisplatin. J. Biol. Chem. 280, 36664-36673
22. Kalivendi, S. V., Konorev, E. A., Cunningham, S., Vanamala, S. K., Kaji, E. H., Joseph, J., and Kalyanaraman, B. (2005) Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium. Biochem. J. 389, 527-539
23. Jain, N., Sudhakar, C., and Swarup, G. (2007) Tumor necrosis factor- induced caspase-1 gene expression. Role of p73. FEBS J. 274, 4396-4407
24. Sudhakar, C., Nagabhushana, A., Jain, N., and Swarup, G. (2009) NF-B mediates tumor necrosis factor-induced expression of optineurin, a negative regulator of NF-B. PLoS ONE 4, e5114
25. Li, C., Zang, Y., Sen, M., Leeman-Neill, R. J., Man, D. S., Grandis, J. R., and Johnson, D. E. (2009) Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Mol. Cancer Ther. 8, 2211-2220
26. Oerlemans, R., Franke, N. E., Assaraf, Y. G., Cloos, J., van Zantwijk, I., Berkers, C. R., Scheffer, G. L., Debipersad, K., Vojtekova, K., Lemos, C., van der Heijden, J. W., Ylstra, B., Peters, G. J., Kaspers, G. L., Dijkmans, B. A., Scheper, R. J., and Jansen, G. (2008) Molecular basis of bortezomib resistance: proteasome subunit 5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112, 2489-2499
27. Mora, L. B., Buettner, R., Seigne, J., Diaz, J., Ahmad, N., Garcia, R., Bowman, T., Falcone, R., Fairclough, R., Cantor, A., Muro-Cacho, C., Livingston, S., Karras, J., Pow-Sang, J., and Jove, R. (2002) Constitutive activation of STAT3 in human prostate tumors and cell lines: direct inhibition of STAT3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 62, 6659-6666
28. Schust, J., Sperl, B., Hollis, A., Mayer, T. U., and Berg, T. (2006) Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 13, 1235-1242
29. Iwamaru, A., Szymanski, S., Iwado, E., Aoki, H., Yokoyama, T., Fokt, I., Hess, K., Conrad, C., Madden, T., Sawaya, R., Kondo, S., Priebe, W., and Kondo, Y. (2007) A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26, 2435-2444
30. Kotha, A., Sekharam, M., Cilenti, L., Siddiquee, K., Khaled, A., Zervos, A. S., Carter, B., Turkson, J., and Jove, R. (2006) Resveratrol inhibits Src and STAT3 signaling and induces the apoptosis of malignant cells containing activated STAT3 protein. Mol. Cancer Ther. 5, 621-629
31. Zhao, M., Gao, F. H., Wang, J. Y., Liu, F., Yuan, H. H., Zhang, W. Y., and Jiang, B. (2011) JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer. Lung Cancer 73, 366-374
32. Zhou, J., Ong, C. N., Hur, G. M., and Shen, H. M. (2010) Inhibition of the JAK-STAT3 pathway by andrographolide enhances chemosensitivity of cancer cells to doxorubicin. Biochem. Pharmacol. 79, 1242-1250
33. Wang, X., Xu, H., Ju, D., and Xie, Y. (2008) Disruption of Rpn4-induced proteasome expression in Saccharomyces cerevisiae reduces cell viability under stressed conditions. Genetics 180, 1945-1953
34. Yuan, Z. L., Guan, Y. J., Chatterjee, D., and Chin, Y. E. (2005) STAT3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307, 269-273
35. Abdulghani, J., Gu, L., Dagvadorj, A., Lutz, J., Leiby, B., Bonuccelli, G., Lisanti, M. P., Zellweger, T., Alanen, K., Mirtti, T., Visakorpi, T., Bubendorf, L., and Nevalainen, M. T. (2008) STAT3 promotes metastatic progression of prostate cancer. Am. J. Pathol. 172, 1717-1728
36. Traish, A. M., and Morgentaler, A. (2009) Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br. J. Cancer 101, 1949-1956
37. Yu, H., Pardoll, D., and Jove, R. (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798-809
38. Mizoguchi, M., Betensky, R. A., Batchelor, T. T., Bernay, D. C., Louis, D. N., and Nutt, C. L. (2006) Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J. Neuropathol. Exp. Neurol. 65, 1181-1188
39. Gan, Y., Shi, C., Inge, L., Hibner, M., Balducci, J., and Huang, Y. (2010) Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene 29, 4947-4958
40. de Wilt, L. H., Jansen, G., Assaraf, Y. G., van Meerloo, J., Cloos, J., Schimmer, A. D., Chan, E. T., Kirk, C. J., Peters, G. J., and Kruyt, F. A. (2012) Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. Biochem. Pharmacol. 83, 207-217
41. Patterson, S. G., Wei, S., Chen, X., Sallman, D. A., Gilvary, D. L., Zhong, B., Pow-Sang, J., Yeatman, T., and Djeu, J. Y. (2006) Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 25, 6113-6122
42. Bard, J. D., Gelebart, P., Amin, H. M., Young, L. C., Ma, Y., and Lai, R. (2009) Signal transducer and activator of transcription 3 is a transcriptional factor regulating the gene expression of SALL4. FASEB J. 23, 1405-1414
43. Liu, G., Rogers, J., Murphy, C. T., and Rongo, C. (2011) EGF signalling activates the ubiquitin proteasome system to modulate C. elegans lifespan. EMBO J. 30, 2990-3003
44. Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R. Z., Kuter, D., Limentani, S. A., Lee, S., Hideshima, T., Esseltine, D. L., Kauffman, M., Adams, J., Schenkein, D. P., and Anderson, K. C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609-2617
45. Fisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., Stadtmauer, E. A., O'Connor, O. A., Shi, H., Boral, A. L., and Goy, A. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 24, 4867-4874
46. Ri, M., Iida, S., Nakashima, T., Miyazaki, H., Mori, F., Ito, A., Inagaki, A., Kusumoto, S., Ishida, T., Komatsu, H., Shiotsu, Y., and Ueda, R. (2010) Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 24, 1506-1512
47. Lü, S., Yang, J., Chen, Z., Gong, S., Zhou, H., Xu, X., and Wang, J. (2009) Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line. Exp. Hematol. 37, 831-837
48. Politou, M., Karadimitris, A., Terpos, E., Kotsianidis, I., Apperley, J. F., and Rahemtulla, A. (2006) No evidence of mutations of the PSMB5 (-5 subunit of proteasome) in a case of myeloma with clinical resistance to bortezomib. Leuk. Res. 30, 240-241
49. Lichter, D. I., Danaee, H., Pickard, M. D., Tayber, O., Sintchak, M., Shi, H., Richardson, P. G., Cavenagh, J., Bladé, J., Façon, T., Niesvizky, R., Alsina, M., Dalton, W., Sonneveld, P., Lonial, S., van de Velde, H., Ricci, D., Esseltine, D. L., Trepicchio, W. L., Mulligan, G., and Anderson, K. C. (2012) Sequence analysis of-subunit genes of the 20 S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood 120, 4513-4516
50. Leung-Hagesteijn, C., Erdmann, N., Cheung, G., Keats, J. J., Stewart, A. K., Reece, D. E., Chung, K. C., and Tiedemann, R. E. (2013) Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 24, 289-304
51. Chen, S., Blank, J. L., Peters, T., Liu, X. J., Rappoli, D. M., Pickard, M. D., Menon, S., Yu, J., Driscoll, D. L., Lingaraj, T., Burkhardt, A. L., Chen, W., Garcia, K., Sappal, D. S., Gray, J., Hales, P., Leroy, P. J., Ringeling, J., Rabino, C., Spelman, J. J., Morgenstern, J. P., and Lightcap, E. S. (2010) Genomewide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res. 70, 4318-4326